- Cyrano Therapeutics Announces CYR-064 Phase 2 FLAVOR Trial Results to be Featured at …
PRNewswire/ — Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company developing novel treatments for smell and taste disorders … - AxoGen: Q2 Earnings Snapshot | kvue.com
The regenerative medicine company posted revenue of $69.7 million in the period. AxoGen expects full-year revenue of $279 million. AxoGen shares … - Integra LifeSciences's (NASDAQ:IART) Q2 CY2026 Earnings Results: Revenue In Line With …
Company Overview. Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures … - Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 …
RMAT designation is intended to help expedite development of new regenerative medicines that have potential to treat serious medical conditions … - Multi-omic analysis of androgen-deprived human testes reveals Sertoli cell regulation and …
Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China. Yifei Guo, Xiaoyan Wang & Jingtao Guo. Department of Reproductive Medicine …
